Figures & data
Figure 1. Schematic representation of the non-covalently functionalized SWNT with DOTAP.
Figure 3. siRNA bound, condensed and stabilized by SWNT–DOTAP. (A) Gel retardation assay at varying siRNA:SWNT–DOTAP mass ratios. (B) TEM images of SWNT–DOTAP/siRNA. Scale bar is 200 nm. (C) The stability of SWNT–DOTAP/siRNA complexes. Intact siRNA (lane 1); naked siRNA after incubation for 6 h (lane 2); complexes (lanes 3 and 4); lanes 3 and 4 indicate samples untreated or destroyed by Triton-X100 after incubation for 6 h, respectively; vector control (lane 5).
Figure 4. The delivery efficiency, RNAi efficiency and tumor cell inhibition of the SWNT–DOTAP/siRNA complexes in PC-3 cells. (A and B) Transfection efficiency of the complexes detected by flow cytometry and fluorescence microscopy, respectively. FAM-labeled siRNA were used. (C) Gene silencing assessed by RT-PCR. (D) Cell inhibition measured by SRB assays. **p < 0.01 versus the vector group.
Figure 5. Summary of the reasons through which SWNT–DOTAP enhancing siRNA delivery, RNAi efficiency and tumor cell inhibition. **p < 0.01 vs. the vector group.
